Hoshino Yusuke, Arai Junichi, Cho Kazutoshi, Yukitake Yoshiya, Kajikawa Daigo, Hinata Ayako, Miura Rena
Department of Neonatology, Ibaraki Children's Hospital, Mito, Japan; Child Health and Cancer Research Center, Ibaraki Children's Hospital, Mito, Japan.
Department of Neonatology, Ibaraki Children's Hospital, Mito, Japan.
Pediatr Neonatol. 2023 Jan;64(1):61-67. doi: 10.1016/j.pedneo.2022.08.002. Epub 2022 Aug 28.
Respiratory distress syndrome (RDS) is characterized by a lack of lung surfactant; therefore, biochemical evidence of surfactant deficiency is needed to diagnose RDS. European guidelines recommend surfactant administration when patients need fraction of inspired oxygen exceeding 0.3 on continuous positive airway pressure or intubation. We hypothesized that the European guidelines for surfactant administration were not adopted in Japan because of the lack of RDS diagnosis. This study aimed to investigate neonatologists' attitudes and practices regarding the diagnosis and management of RDS in Japan.
A mail-based survey regarding the diagnosis and management of RDS was conducted at 111 level III or ΙV neonatal intensive care units in Japan. The questionnaire was completed by the person in charge of each unit.
The overall response rate for the questionnaire was 91% (101/111 centers). All respondents referred to chest radiography, and the majority (83%) of respondents referred to stable microbubble rating (SMR) for establishing the diagnosis of RDS. Surfactant administration was chiefly based on clinical conditions, chest radiography, and/or SMR. Most units in Japan do not adopt the European criteria for surfactant administration.
In Japan, chest radiography and/or SMR are commonly used for the diagnosis of RDS and as the rationale for surfactant administration. Further studies from other countries are required to establish the ideal criteria for surfactant administration.
呼吸窘迫综合征(RDS)的特征是缺乏肺表面活性物质;因此,需要有表面活性物质缺乏的生化证据来诊断RDS。欧洲指南建议,当患者在持续气道正压通气或插管时需要的吸入氧分数超过0.3时,给予表面活性物质。我们推测,由于缺乏RDS诊断,日本未采用欧洲表面活性物质给药指南。本研究旨在调查日本新生儿科医生对RDS诊断和管理的态度及做法。
在日本的111个Ⅲ级或Ⅳ级新生儿重症监护病房进行了一项关于RDS诊断和管理的邮寄调查。问卷由每个病房的负责人填写。
问卷的总体回复率为91%(101/111个中心)。所有受访者都参考了胸部X线检查,大多数(83%)受访者参考了稳定微泡评分(SMR)来确立RDS的诊断。表面活性物质的给药主要基于临床情况、胸部X线检查和/或SMR。日本大多数病房未采用欧洲表面活性物质给药标准。
在日本,胸部X线检查和/或SMR常用于RDS的诊断,并作为表面活性物质给药的依据。需要其他国家开展进一步研究以确立表面活性物质给药的理想标准。